SUMMARY Thirty patients with Parkinson's disease were treated for four weeks with levodopa combined with an inhibitor of extracerebral dopa decarboxylase, L-alpha-methyldopahydrazine (MK 486). The therapeutic results were compared with the effects of treatment of a group of 40 patients with levodopa alone. Patients treated with the combined therapy improved more rapidly, had less nausea and vomiting, and required a much smaller dose of levodopa than patients treated with levodopa by itself.
Levodopa is the best treatment available for Parkinson's disease, but it takes weeks or months of treatment to achieve the maximum improvement and about one quarter of patients gain no benefit or cannot tolerate the drug. Dose limiting side-effects are common, occurring in about 75%0 of patients. Nausea and vomiting, involuntary movements, psychiatric disturbances, postural hypotension, and cardiac arrhythmias often limit or prohibit effective treatment.
The therapeutic effect of levodopa is thought to be due to its conversion to dopamine in the brain, thus reversing the depletion of this catecholamine in the corpus striatum of patients with Parkinson's disease. Dopamine given parenterally does not enter the brain; most of an oral dose of levodopa does not reach the brain parenchyma, for it is converted into dopamine and other metabolites outside the brain. This extracerebral formation of dopamine and other catecholamines may be responsible for some of the side-effects of levodopa treatment and considerably reduces the amount of levodopa available to the brain cell.
The enzyme dopa decarboxylase is responsible for the conversion of levodopa to dopamine both in the brain and in extracerebral tissues such as gut wall, heart, kidney, and cerebral capillaries.
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Drugs that preferentially inhibit extracerebral decarboxylase have been developed (Udenfriend, Zaltman-Nirenberg, Gordon, and Spector, 1966; Bartholini, Burkard, Pletscher, and Bates, 1967) and used in an attempt to improve the therapeutic response to levodopa (Birkmayer, 1969; Siegfried, Ziegler, Regli, Fischer, Kaufmann, and Perret, 1969; Tissot, Gaillard, Guggisberg, Gauthier, and Ajuriaguerra, 1969; Barbeau, Gillo-Joffrey, and Mars, 1971; Calne, Reid, Vakil, Rao, Petrio, Pallis, Gawler, Thomas, and Hilson, 1971) . As these drugs do not readily enter the brain, their inhibitory action is mainly peripheral and they do not significantly affect intracerebral dopamine formation from levodopa.
We report here our experience of the use of a combination of levodopa and the extracerebral decarboxylase inhibitor L-alpha-methyldopahydrazine (MK 486; Porter, Watson, Titus, Totaro, and Byer, 1962) (Table 1) . The improvement was rapid in onset and on some occasions dramatic. The majority of patients had both subjective and objective improvement within 14 days of starting treatment (Figure) . There was no significant difference between the response at two and four weeks of treatment. Posture (24) 8-8 (± 3 9) 53 (±36) P< 0-001
The maximum possible score is given in parentheses. Figure) .
The final mean dose of levodopa when given with MK 486 was 10 g per day (range 0.15-2'5 g per day). The final mean dose of levodopa when given by itself was 2 1 g per day (range 0-5-5 0 g per day). Cotzias, Papavasiliou and Gellene, 1969; Calne et al., 1971; Yahr, Duvoisin, Mendoza, Schear, and Barrett, 1971 . Similar results have also been obtained by combining levodopa with the different extracerebral decarboxylase inhibitor N1-(DL-seryl)-N2-(2,3,4,-trihydroxybenzyl)-hydrazine (RO4-4602) (Birkmayer, 1969; Siegfried et al., 1969; Tissot et al., 1969; Barbeau et al., 1971) . Combined treatment with levodopa and MK 486 seems to achieve the same therapeutic response as levodopa alone, but improvement is much more rapid in onset with marked reduction in nausea and vomiting. There is also a considerable reduction in the dose of levodopa required for maximum benefit. It is not known whether anticholinergic drugs and amantadine have an additive effect when given with dopa decarboxylase inhibitors and levodopa, but these additional drugs have also been used in many patients in the trials referred to. Decrease of the incidence of nausea and vomiting is a significant gain to the patient and the initial period of levodopa treatment is rendered much more tolerable.
Combined therapy, however, does not seem to influence the occurrence of involuntary movements or hallucinations which still prove troublesome in many patients. Levodopa, due to a peripheral action of its metabolites, carries some risk of inducing cardiac arrhythmias in patients with heart disease. Combined treatment with MK 486 may reduce the peripheral formation of levodopa metabolites and reduce the risk of cardiac arrhythmias. Similarly, there may be a reduction in the incidence of severe postural hypotension, although there is some evidence to suggest this is due to a central, rather than peripheral action of levodopa (Watanabe, Chase, and Cardon, 1970) .
The combination of levodopa and MK 486 may influence the activity of certain hepatic microsomal enzyme systems for it delays the plasma clearance of antipyrine (Vessell, Ng, Passananti, and Chase, 1971) . The possibility that MK 486 alters the metabolism of other drugs given concurrently thus needs to be explored further and the long-term effects of MK 486 determined. There are patients who cannot tolerate adequate therapeutic doses of levodopa alone, but who respond satisfactorily to combined treatment with MK 486. In addition, many patients suffer distressing nausea and vomiting to gain the therapeutic benefits of levodopa and in these patients a more acceptable form of therapy is combined treatment with a dopa decarboxylase inhibitor. However, there remain limitations even to such combined treatment, for a significant proportion of patients still fail to improve and involuntary movements remain the most common dose-limiting side-effect.
